Dr. Paul Harch, Clinical Professor and Director of Hyperbaric Medicine at LSU Health New Orleans School of Medicine, and Dr. Edward Fogarty, Chairman of Radiology at the University of North Dakota School of Medicine, report the first PET scan-documented case of improvement in brain metabolism in Alzheimer’s disease in a patient treated with hyperbaric oxygen therapy (HBOT).
The report, published in the current issue of the peer-reviewed journal Medical Gas Research, is available here.
The authors report the case of a 58-year-old female who had experienced five years of cognitive decline, which began accelerating rapidly. Single photon emission computed tomography (SPECT) suggested Alzheimer’s disease. The diagnosis was confirmed by 18Fluorodeoxyglucose (18FDG) positron emission tomography (PET) brain imaging, which revealed global and typical metabolic deficits in Alzheimer’s.
The patient underwent a total of 40 HBOT treatments – five days a week over 66 days. Each treatment consisted of 1.15 atmosphere absolute/50 minutes total treatment time. After 21 treatments, the patient reported increased energy and level of activity, better mood and ability to perform daily living activities as well as work crossword puzzles. After 40 treatments, she reported increased memory and concentration, sleep, conversation, appetite, ability to use the computer, more good days (5/7) than bad days, resolved anxiety, and decreased disorientation and frustration. Tremor, deep knee bend, tandem gain, and motor speed were also improved. Repeat 18FDG PET imaging one month post-HBOT showed global 6.5–38% improvement in brain metabolism.
“We demonstrated the largest improvement in brain metabolism of any therapy for Alzheimer’s disease,” notes Dr. Harch. “HBOT in this patient may be the first treatment not only to halt, but temporarily reverse disease progression in Alzheimer’s disease.”
The report also contains video imaging, including unique rotating PET 3D Surface Reconstructions, which allow the lay person to easily see the improvements in brain function.
“PET imaging is used around the world as a biomarker in oncology and cardiology to assay responses to therapy,” says Dr. Fogarty. “We now have an irrefutable biomarker system that this intervention has promise where no other real hope for recovery of dementia has ever existed before.”
The physicians report that two months post-HBOT, the patient felt a recurrence in her symptoms. She was retreated over the next 20 months with 56 HBOTs (total 96) at the same dose, supplemental oxygen, and medications with stability of her symptoms and Folstein Mini-Mental Status exam.
According to the National Institutes of Health, “Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks. It is the most common cause of dementia in older adults. Alzheimer’s disease is currently ranked as the sixth leading cause of death in the United States, but recent estimates indicate that the disorder may rank third, just behind heart disease and cancer, as a cause of death for older people.”
The authors note that four pathological processes have been identified and primary treatment is with acetylcholinesterase inhibitors or the N-methyl-D-aspartate receptor antagonist memantine, which have been shown to have a positive impact on Alzheimer’s disease progression with no significant disease-modifying effects.
HBOT is an epigenetic modulation of gene expression and suppression to treat wounds and disease pathophysiology, particularly inflammation. HBOT targets all four of the pathological processes of AD by affecting the microcirculation; mitochondrial dysfunction, and biogenesis; reducing amyloid burden and tau phosphorylation; controlling oxidative stress; and reducing inflammation.
The first successful HBOT-treated case of Alzheimer’s disease was published in 2001. The present case report is the first patient in a series of 11 HBOT-treated patients with Alzheimer’s disease whose symptomatic improvement is documented with 18fluorodeoxyglucose positron emission tomography (18FDG PET).“Our results suggest the possibility of treating Alzheimer’s disease long-term with HBOT and pharmacotherapy,” concludes Harch.
Learn more: HBOT Showed Improvement in Alzheimer’s Disease
The Latest on: Hyperbaric oxygen therapy
via Google News
The Latest on: Hyperbaric oxygen therapy
- Local doctor continues to push VA to approve Hyperbaric Oxygen Therapy for veteranson January 2, 2020 at 8:35 pm
I couldn't walk without some sort of narcotic. I saw my life was dwindling away because of pain medication," said Durrance. Desperate for an alternative -- his wife inquired about the hyperbaric ...
- Program seeks veterans with PTSD, brain trauma for hyperbaric therapyon December 26, 2019 at 6:51 pm
At one time, he was confined to a wheelchair until a nonprofit veterans’ organization offered him an alternative to traditional pain management: hyperbaric oxygen therapy. After several weeks of ...
- HBOT Devices Market Opportunities & Challenges During the Forecast Period, 2019-2025 - ResearchAndMarkets.comon December 18, 2019 at 4:13 am
DUBLIN--(BUSINESS WIRE)--The "HBOT Devices (Hyperbaric Oxygen Therapy) Market Size, Outlook and Growth Opportunities, 2019- 2025" report has been added to ResearchAndMarkets.com's offering. The 'HBOT ...
- How hyperbaric oxygen therapy heals woundson December 9, 2019 at 5:53 am
Dr. Aurel Mihai explains why hyperbaric oxygen therapy can be a powerful tool in treating patients with stubborn, non-healing wounds. What are the main causes of wounds? Venous stasis where an ...
- Hyperbaric oxygen therapy for Tigeron November 29, 2019 at 7:34 pm
The actor has been sharing pictures and videos from day one of the shoot. Recently Tiger shared a video on his Instagram story where he is undergoing hyperbaric oxygen therapy. For the uninitiated, ...
- North America Hyperbaric Oxygen Therapy (Hbot) De Market Demand, Growth Opportunities and Top Key Players Analysis Report 2028on November 24, 2019 at 8:47 pm
Nov 25, 2019 (AmericaNewsHour) -- CRIFAX added a report on 'North America Hyperbaric Oxygen Therapy (Hbot) Devices Market, 2020-2028' to its database of market research collaterals consisting of ...
- Hyperbaric Oxygen Therapy (HBOT) Devices Market Potential Growth, Share, Demand and Analysis of Key Players- Research Forecasts to 2024on November 11, 2019 at 5:55 pm
Nov 12, 2019 (The Expresswire) -- Hyperbaric Oxygen Therapy (HBOT) Devices Market analysis report contains all study material about Market Overview, Growth, Demand and Forecast Research in all over ...
- Hyperbaric oxygen therapy safe, effective for treating symptoms of late radiation cystitison November 7, 2019 at 1:23 pm
Hyperbaric oxygen therapy safely relieved symptoms of late radiation cystitis among patients who received radiotherapy for cancer in the pelvic region, according to results of the randomized phase ...
- Hyperbaric oxygen therapy can relieve symptoms and side-effects of radiotherapyon October 16, 2019 at 12:24 pm
Hyperbaric oxygen therapy (HBOT) can relieve self-reported symptoms and side-effects of radiotherapy against cancer in the pelvic region, a study shows. After 30-40 sessions in a hyperbaric chamber, ...
- Oxygen in hyperbaric chamber provides relief after radiotherapyon October 14, 2019 at 5:00 pm
Hyperbaric oxygen therapy (HBOT) can relieve self-reported symptoms and side-effects of radiotherapy against cancer in the pelvic region, a study shows. After 30–40 sessions in a hyperbaric chamber, ...
via Bing News